江西天新药业股份有限公司 投资者关系活动记录表 编号：2024-002 □特定对象调研 □分析师会议 □媒体采访 业绩说明会 投资者关系活动 □新闻发布会 □路演活动 类别 □现场参观 □其他: 参与单位名称及 线上参与公司2023年度暨2024年第一季度业绩说明会的全体 人员姓名 投资者 时间 2024年5月28日 14:00-15:00 地点 上证路演中心（http://roadshow.sseinfo.com/） 董事、总经理：余小兵 上市公司接待人 独立董事：杨延莲 员姓名 财务总监：罗雪林 ...

江西天新药业股份有限公司 投资者关系活动记录表 编号：2024-002 □特定对象调研 □分析师会议 □媒体采访 业绩说明会 投资者关系活动 □新闻发布会 □路演活动 类别 □现场参观 □其他: 参与单位名称及 线上参与公司2023年度暨2024年第一季度业绩说明会的全体 人员姓名 投资者 时间 2024年5月28日 14:00-15:00 地点 上证路演中心（http://roadshow.sseinfo.com/） 董事、总经理：余小兵 上市公司接待人 独立董事：杨延莲 员姓名 财务总监：罗雪林 ...

证券代码：603235 证券简称：天新药业 公告编号：2024-030 江西天新药业股份有限公司 关于参加江西辖区上市公司 2024 年投资者 网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为进一步加强与投资者的互动交流，江西天新药业股份有限公司（以下简 称“公司”）将参加由江西省上市公司协会与深圳市全景网络有限公司联合举 办的“2024 年江西辖区上市公司投资者集体接待日活动”，现将相关事项公告 如下： 本次活动将采用网络远程的方式举行，投资者可登录“全景路演”网站 (https://rs.p5w.net)，或关注微信公众号：全景财经，或下载全景路演 APP，参 与本次互动交流，活动时间为 2024 年 5 月 17 日（周五）15:00-17:00。届时公 司高管将在线就公司 2023年度业绩、公司治理、发展战略、经营状况和可持续 发展等投资者关心的问题，与投资者进行沟通与交流，欢迎广大投资者踊跃参 与。 ...

特此公告 江西天新药业股份有限公司董事会 2024 年 4 月 30 日 公司负责人：许江南 主管会计工作负责人：罗雪林 会计机构负责人：梁亮 母公司利润表 | --- | --- | --- | |--------------|-------------------|-------------------| | 项目 | 2024 年第一季度 | 2023 年第一季度 | | 一、营业收入 | 497,412,857.03 | 578,385,715.56 | | 减：营业成本 | 317,621,405.06 | 405,616,576.96 | | 税金及附加 | 4,905,144.54 | 3,902,759.18 | | 销售费用 | 3,079,008.12 | 5,272,037.85 | | 管理费用 | 25,214,608.45 | 28,643,435.92 | | 研发费用 | 9,686,583.82 | 6,552,836.78 | | 财务费用 | -25,750,850.05 | 156,951.62 | 14 / 17 2024 年第一季度报告 | --- | --- | ...

证 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 告 司 究 报 公 研 2024 年 04 月 24 日 | --- | --- | --- | |-----------------------------------------------------------------------------|---------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

Accounting Methods and Revenue Recognition - The company adjusts the accounting method for remaining equity after losing control of a subsidiary, either using the equity method or recognizing the difference between fair value and book value as current profit or loss[1] - Revenue from export sales is recognized based on the trade terms, with different recognition points for various trade settlement methods such as CIF, FOB, and DDP[5] - Revenue from domestic sales is recognized upon delivery to the customer's specified location and customer confirmation of receipt[9] Asset Management and Impairment - Construction in progress is recognized when economic benefits are likely to flow in and costs can be reliably measured, and is transferred to fixed assets upon reaching the intended usable state[2] - The company reviews the useful life and amortization method of finite-lived intangible assets annually, adjusting estimates and recognizing impairment if future economic benefits are no longer expected[4] - The company assesses impairment of assets related to contract costs, recognizing impairment losses if the carrying amount exceeds the expected remaining consideration minus estimated costs[10] - The company's intangible assets have a book value of 192,311,293.45 RMB at the end of the period, with a cumulative amortization of 20,669,830.54 RMB[34] - The company's engineering materials have a book value of 82,350,552.80 RMB at the end of the period, with a provision for impairment of 721,797.20 RMB[28] Government Grants and Subsidies - Government grants are recognized upon receipt, with specific criteria for recognizing grants based on expected amounts and compliance with fiscal support policies[7] - Government subsidies are recognized as deferred income and amortized over the useful life of related assets, with any remaining balance transferred to profit or loss upon disposal of the assets[11] - The company's deferred tax assets at the end of the period were RMB 85,304,542.97, with a significant portion coming from government subsidies of RMB 58,661,705.01[39][40] - Total government subsidies received increased to 138,021,872.10 RMB from 29,916,370.85 RMB, a significant growth of 361.4%[67] Financial Assets and Liabilities - The company holds no financial assets measured at fair value through profit or loss as of the reporting period, compared to RMB 230 million at the beginning of the period[13] - Bank acceptance bills amounted to RMB 50.49 million at the end of the period, all of which were not derecognized[14] - The balance of bank acceptance notes was RMB 53.29 million at the end of the period, with no bad debt provision[15] - The company's financial assets and liabilities not measured at fair value have a book value close to their fair value[169] - The fair value of receivables financing at the end of the period is RMB 3,292,184.01, classified under Level 2 fair value measurement[166] Inventory and Cost Management - Inventory increased from RMB 4.56 million to RMB 13.67 million, with significant growth in work-in-progress and finished goods[20] - Raw materials inventory decreased from RMB 83.18 million to RMB 39.66 million, while finished goods inventory increased from RMB 198.48 million to RMB 307.34 million[23] - The total inventory balance at the end of the period was RMB 492.63 million, with a provision for inventory impairment of RMB 13.67 million[23] - Operating costs decreased by 19.71% to RMB 1,161,708,799.37, primarily due to lower raw material prices and reduced manufacturing expenses[183][184] Project Investments and Progress - The budget for the Vitamin B5 project is 460,021,300 RMB, with a cumulative investment of 75.44% of the budget, and the project progress is 75.44%[25] - The Vitamin A project has a budget of 781,291,500 RMB, with a cumulative investment of 25.40% of the budget, and the project progress is 25.40%[25] - The Enterprise Research Institute project has a budget of 128,865,500 RMB, with a cumulative investment of 69.20% of the budget, and the project progress is 69.20%[25] - The fine chemical project has a budget of 500,000,000 RMB, with a cumulative investment of 2.95% of the budget, and the project progress is 2.95%[25] - The Le Ping Industrial Park cogeneration project has a budget of 350,000,000 RMB, with a cumulative investment of 12.07% of the budget, and the project progress is 12.07%[25] - The other fine chemical product project has a budget of 3,690,000,000 RMB, with a cumulative investment of 5.80% of the budget, and the project progress is 5.80%[25] - The Qingtongxia Industrial Park thermal power island project has a budget of 1,464,730,000 RMB, with a cumulative investment of 2.71% of the budget, and the project progress is 2.71%[25] - The total budget for all projects is 7,374,908,300 RMB, with a cumulative investment of 342,940,892.04 RMB[25] Financial Performance and Metrics - The company's total revenue for the year 2023 was RMB 1,881,993,019.35, with a cost of RMB 1,161,708,799.37, resulting in a gross profit of RMB 720,284,219.98[50] - B-vitamins contributed the majority of the revenue, generating RMB 1,650,309,734.61, with a cost of RMB 958,705,177.48[52] - Domestic sales accounted for RMB 782,140,234.10, while international sales contributed RMB 1,099,852,785.25[52] - The company's net profit for the current period was 475,853,298.64 RMB, a decrease from the previous period's 622,115,124.53 RMB[98] - Revenue for 2023 was 1,881,993,019.35 yuan, a decrease of 18.34% compared to the previous year[120] - Net profit attributable to shareholders was 475,853,298.64 yuan, down 23.51% year-on-year[120] - Operating cash flow increased by 20.21% to 729,212,499.59 yuan[120] - Basic earnings per share (EPS) decreased by 27.81% to 1.09 yuan per share[121] - Weighted average return on equity (ROE) dropped by 10.23 percentage points to 11.55%[121] Cash Flow and Financing Activities - The company's cash and cash equivalents increased by 238,239,548.75 RMB, reaching a total of 2,307,768,991.53 RMB at the end of the period[98] - The company's short-term borrowing increased by 100,000,000.00 RMB, with a total of 100,072,222.22 RMB at the end of the period[96] - The company's total investment in financial products was 1,798,000,000.00 RMB, an increase from the previous period's 1,622,010,000.00 RMB[94] - The company's total cash outflow related to leasing activities was 3,383,139.22 RMB[105] - The company's total cash outflow related to financing activities was 3,171,139.22 RMB, a significant decrease from the previous period's 30,315,099.62 RMB[95] - The company's total cash outflow related to investment activities was 1,798,000,000.00 RMB, an increase from the previous period's 1,622,010,000.00 RMB[94] - The company's total cash outflow related to operating activities was 729,212,499.59 RMB, an increase from the previous period's 606,613,170.14 RMB[98] - The company's total cash outflow related to the payment of dividends was 310,823,800.00 RMB[96] - The company's total cash outflow related to the payment of IPO issuance fees was 26,602,479.62 RMB in the previous period[95] Expenses and Costs - Total management expenses decreased to 136,349,813.27 RMB from 144,180,344.74 RMB, a reduction of 5.4%[53] - R&D expenses increased to 111,964,592.30 RMB from 89,462,842.32 RMB, a growth of 25.1%[54] - Government subsidies decreased to 47,390,378.61 RMB from 53,254,038.41 RMB, a reduction of 11.0%[55] - Investment income from bank financial products decreased to 2,454,302.84 RMB from 4,653,541.60 RMB, a reduction of 47.3%[56] - Interest income increased significantly to 74,460,498.56 RMB from 16,251,609.72 RMB, a growth of 358.2%[56] - Credit impairment losses slightly decreased to 3,159,494.22 RMB from 3,233,939.87 RMB, a reduction of 2.3%[59] - Asset impairment losses increased to -12,363,832.71 RMB from -4,157,876.36 RMB, a significant increase in losses[60] - Current income tax expense increased to 111,841,440.48 RMB from 100,786,018.29 RMB, a growth of 11.0%[63] - Total employee compensation increased to 80.16 million yuan from 74.19 million yuan, a rise of 8.05%[107] - Direct material costs rose to 7.26 million yuan from 5.29 million yuan, an increase of 37.25%[107] - Depreciation and amortization expenses surged to 12.35 million yuan from 2.98 million yuan, a significant jump of 315.08%[107] - Other expenses increased to 12.19 million yuan from 7.01 million yuan, up by 73.96%[107] - Total expenses for the period amounted to 111.96 million yuan, up from 89.46 million yuan, a 25.15% increase[107] Market and Industry Analysis - The vitamin industry faced challenges with slowing global economic growth and increased competition[128] - The company achieved domestic registration approval for folic acid raw materials and obtained EU export certification for Vitamin D3 raw materials[129] - The company completed multiple quality system expansion certifications, including ISO22000 for cholesterol and FAMI-QS certification for Vitamin A acetate and 25-hydroxy Vitamin D3[129] - R&D expenses continued to grow rapidly, driving continuous improvement in production levels[130] - The company is steadily advancing projects such as Vitamin A, Vitamin B5, and Ningxia Tianxin, ensuring sustainable development[130] - China's vitamin production in 2023 is expected to reach 434,000 tons, a 4.0% year-on-year increase, accounting for 84.4% of global production[134] - The Chinese vitamin market value in 2023 is projected to be $3.72 billion, a 16.4% year-on-year decrease[134] - The company holds a leading global market share in Vitamin B6 and Vitamin B1, and is in the top tier for biotin and folic acid products[135] - The company has established a strong global competitiveness in B-group vitamins, including Vitamin B6, Vitamin B1, biotin, and folic acid[136] - The company's ABL product, used in pesticide intermediates and Vitamin B1, achieved external sales in 2022 and further expanded in 2023[136] - Vitamin business accounted for 96.30% of the company's main business revenue in 2023, being the primary factor affecting performance fluctuations[141] - Overall downstream demand for vitamins was weak in 2023, leading to increased competitive pressure on the supply side and suppressed prices, contributing to the company's performance decline[141] Corporate Governance and Compliance - The company established Tianxin International Holdings (Hong Kong) Limited in March 2023 with a registered capital of 10,000 HKD[109] - As of December 31, 2023, Tianxin International Holdings (Hong Kong) Limited reported a net loss of 92,783.10 yuan[109] - The company's subsidiary, Ningxia Tianxin Pharmaceutical Co., Ltd., transferred 10,000 yuan of equity in Qingtongxia Tianxin Dingheng Heating Power Co., Ltd., reducing its indirect ownership from 100% to 99.75%[113] - The company's stock is listed on the Shanghai Stock Exchange under the ticker symbol 603235[116] - The company's auditor is Zhonghui Certified Public Accountants, and its continuous supervision sponsor is CITIC Securities[117] - The company's environmental management system is established and maintained in accordance with ISO14001 standards, emphasizing green development and circular economy[143][147] - The company has a comprehensive sales and service network centered in Shanghai, covering Asia, Europe, North America, South America, Oceania, and Africa[148] - The company has obtained various certifications, including FAMI-QS, ISO22000, BRC, Halal, Kosher, and certifications from regulatory bodies in China, the EU, the US, and Japan, ensuring access to high-end markets[149] Debt and Liabilities - The company's debt-to-asset ratio increased to 16.84% as of December 31, 2023, compared to 13.29% in the previous year[163] - Short-term borrowings: RMB 10,104.00 (within one year)[161] - Accounts payable: RMB 12,663.93 (within one year)[161] - Other payables: RMB 857.85 (within one year)[161] - Non-current liabilities due within one year: RMB 312.37[161] - Lease liabilities: RMB 530.04 (total)[162] - Total financial liabilities and contingent liabilities: RMB 25,611.19 (current period) vs RMB 12,783.00 (previous period)[162] - The company's other payables decreased from RMB 10,548,296.39 at the beginning of the period to RMB 8,578,504.58 at the end of the period[173] - The company's non-bank acceptance bills endorsed but not yet due decreased from RMB 60,012,793.35 at the beginning of the period to RMB 50,489,814.34 at the end of the period[177] - The company's government grants increased from RMB 306,156,569.99 at the beginning of the period to RMB 390,788,063.48 at the end of the period, with an increase of RMB 115,419,200.00 and a decrease of RMB 30,787,706.51 during the period[180] - The company's lease liabilities due within 1 year decreased from RMB 3,419,674.54 at the beginning of the period to RMB 3,123,735.24 at the end of the period[176] - The company's long-term payables increased from RMB 4,646,387.50 at the beginning of the period to RMB 5,095,912.47 at the end of the period[178] - The company's prepaid taxes to be transferred decreased from RMB 1,613,296.80 at the beginning of the period to RMB 1,016,999.16 at the end of the period[177] - The company's deposit and guarantee liabilities increased from RMB 175,000.00 at the beginning of the period to RMB 225,000.00 at the end of the period[175] Related Party Transactions - The company's total related party transactions amounted to RMB 3,006.56 million, with the majority coming from sales to related parties at RMB 2,105.95 million[47] - The company's subsidiaries and related parties include Zhejiang Tianxin Pharmaceutical Co., Ltd., Zhejiang Xinweishi Biotechnology Co., Ltd., and Shanghai Newrite Biotechnology Co., Ltd., among others[171] Research and Development - R&D expenses increased by 25.15% to RMB 111,964,592.30, reflecting increased investment in research and development[183] - The company's R&D expense ratio continued to increase during the reporting period, with projects such as Vitamin B5, Vitamin A, and Ningxia Tianxin progressing as planned[142] - The company's production sites have passed FDA certification, and Vitamin B6 and Vitamin B1 (hydrochloride) have obtained FDA DMF filings[143] Sales and Distribution - The company's sales model is primarily direct sales, with distributors handling wholesale or retail[140] - Main business revenue for 2023 was RMB 1,851,390,100, a decrease of 17.83%, mainly due to lower vitamin product prices[185] - Main business costs for 2023 were RMB 1,135,447,100, a decrease of 18.98%, driven by lower raw material prices and reduced manufacturing expenses[185] - Contract liabilities decreased to RMB 21,098,771.55 from RMB 23,341,621.74, indicating a reduction in prepayments from customers[196] Taxation and Deferred Taxes - Deferred tax assets and liabilities are recognized based on temporary differences between book value and tax base, with certain exceptions for transactions not affecting accounting profit or taxable income[8] - The company's internal transactions resulted in unrealized profits of RMB 126,804,672.87, with deferred tax assets of RMB 19,020,700.93[40] - The company's bad debt provision decreased by RMB 3,155,511.19, resulting in a deferred tax asset reduction of RMB 471,116.80[39] - The company's unconfirmed deferred tax assets increased by RMB 21,338,495.70, primarily due to deductible losses of RMB 17,651,718.49[45] - Deferred tax liabilities at the end of the period were RMB 4,179,272.04, primarily due to accelerated depreciation of fixed assets amounting to RMB 2,278,177.38[42] Other Financial Metrics - The total balance of deposits, guarantees, and other receivables decreased from RMB 4.27 million to RMB 2.44 million year-over-year[18] - The provision for bad debts decreased by RMB 1.5 million, resulting in a year-end balance of RMB 738,295.84[21] - The company's long-term prepaid expenses decreased by RMB 1,385,837.04, with the hazardous waste treatment center opening fee being the largest component at RMB 8,021,289.

江西天新药业股份有限公司 投资者关系活动记录表 编号：2023-005 □特定对象调研 □分析师会议 □媒体采访 业绩说明会 投资者关系活动 □新闻发布会 □路演活动 类别 □现场参观 □其他: 参与单位名称及 线上参与公司2023年第三季度业绩说明会的全体投资者 人员姓名 时间 2023年12月14日 15:00-16:00 地点 上证路演中心（http://roadshow.sseinfo.com/） 董事、总经理：余小兵 上市公司接待人 独立董事：刘路遥 员姓名 财务总监：罗雪林 ...

2023 年第三季度报告 单位：元 币种：人民币 证券代码：603235 证券简称：天新药业 江西天新药业股份有限公司 2023 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | --- | --- | |-----------------------------|----------------|-------------------------------------------|------------------|------------------------------------------------ ...

Financial Performance - Revenue for the first half of 2023 decreased by 9.73% to RMB 1,120,547,937.20 compared to the same period last year[5] - Net profit attributable to shareholders of the listed company decreased by 17.77% to RMB 329,956,160.32[5] - Basic earnings per share decreased by 26.47% to RMB 0.75[6] - Weighted average return on equity decreased by 11.19 percentage points to 7.81%[6] - Revenue for the period was 1,120,547,937.20 RMB, a decrease of 9.73% compared to the same period last year[80] - Net profit attributable to shareholders was RMB 330 million, down 17.77% compared to the same period last year[92] - Revenue for the first half of 2023 was RMB 1.121 billion, a decrease of 9.73% year-over-year[92] - The company's revenue from nutritional products was 1,053,876,315.45 RMB, with a gross margin of 37.89%, representing a decrease of 11.97% in revenue and a 4.40 percentage point decrease in gross margin compared to the previous year[76] - Revenue from B-vitamins was 980,187,143.87 RMB, with a gross margin of 39.87%, showing a decrease of 10.56% in revenue and a 4.10 percentage point decrease in gross margin compared to the previous year[76] - The company's total revenue was 1,102,324,478.47 RMB, with a gross margin of 37.51%, reflecting a decrease of 9.19% in revenue and a 4.90 percentage point decrease in gross margin compared to the previous year[76] - Domestic sales revenue was 450,389,400.82 RMB, with a gross margin of 38.00%, indicating a 3.24% increase in revenue but a 4.99 percentage point decrease in gross margin compared to the previous year[76] - Export sales revenue was 651,935,077.65 RMB, with a gross margin of 37.17%, showing a decrease of 16.16% in revenue and a 4.91 percentage point decrease in gross margin compared to the previous year[76] Cash Flow and Operating Activities - Cash flow from operating activities increased by 61.77% to RMB 401,420,301.67[5] - Net cash flow from operating activities increased by 61.77% to 401,420,301.67 RMB[80] - Net cash flow from investing activities was 29,091,940.48 RMB, compared to -66,761,791.88 RMB in the same period last year[80] - Financial expenses were -88,546,844.69 RMB, primarily due to increased interest from RMB and USD deposits[79] Assets and Liabilities - Total assets increased by 2.77% to RMB 4,809,368,353.09 compared to the end of last year[5] - Total assets as of June 30, 2023, amounted to 4,809,368,353.09, compared to 4,679,962,858.74 as of December 31, 2022[176] - Cash and cash equivalents increased to 2,363,328,253.22 as of June 30, 2023, from 2,069,864,246.58 as of December 31, 2022[176] - Accounts receivable decreased to 249,343,319.51 as of June 30, 2023, from 259,397,909.74 as of December 31, 2022[176] - Inventory decreased to 397,343,495.17 as of June 30, 2023, from 470,628,636.85 as of December 31, 2022[176] - Fixed assets decreased to 1,153,548,267.87 as of June 30, 2023, from 1,180,323,935.24 as of December 31, 2022[180] - Construction in progress increased to 190,737,514.27 as of June 30, 2023, from 122,640,615.79 as of December 31, 2022[180] - Intangible assets increased to 194,843,819.93 as of June 30, 2023, from 109,814,312.46 as of December 31, 2022[180] - Total current liabilities increased to 380,477,375.20 as of June 30, 2023, from 311,178,261.53 as of December 31, 2022[180] - Accounts payable decreased to 70,058,333.62 as of June 30, 2023, from 108,545,290.36 as of December 31, 2022[180] - Employee benefits payable decreased to 54,777,450.21 as of June 30, 2023, from 99,117,377.05 as of December 31, 2022[180] - The company's monetary funds increased to 2,326,933,446.22 RMB as of June 30, 2023, compared to 2,054,246,268.02 RMB at the end of 2022[182] - Trade receivables decreased slightly to 257,022,544.27 RMB from 261,588,692.80 RMB over the same period[182] - Inventory levels decreased to 406,746,915.52 RMB from 454,808,652.06 RMB[182] - Prepayments increased significantly to 88,675,349.92 RMB from 49,814,225.84 RMB[182] - The company's total liabilities increased to 727,286,341.51 RMB from 621,981,219.02 RMB[197] - Total owner's equity increased to 4,082,082,011.58 RMB from 4,057,981,639.72 RMB[197] - Retained earnings grew to 1,443,478,691.15 RMB from 1,424,346,330.83 RMB[197] - The company's total assets increased to 4,809,368,353.09 RMB from 4,679,962,858.74 RMB[197] - Total current assets increased slightly to 3,177,105,069.57 from 3,171,456,023.36[198] - Long-term equity investments rose significantly to 145,938,705.95 from 50,938,705.95[198] - Fixed assets decreased to 1,068,703,840.22 from 1,092,555,719.72[198] - Construction in progress increased to 170,684,734.47 from 119,851,727.95[198] - Intangible assets grew to 172,988,645.37 from 165,489,853.23[198] - Deferred tax assets increased to 52,147,418.85 from 48,319,829.30[198] - Total non-current assets rose to 1,630,551,142.25 from 1,492,123,966.45[198] - Total assets increased to 4,807,656,211.82 from 4,663,579,989.81[198] - Current liabilities increased to 363,365,589.48 from 294,909,140.99[198] - Short-term borrowings stood at 100,065,000.00[198] Products and Market Position - The company's main products include Vitamin B6, Vitamin B1, Biotin, Folic Acid, Vitamin D3, and Vitamin E powder, primarily used in feed, pharmaceuticals, and food industries[8] - The company has established stable partnerships with thousands of customers, with domestic sales covering all provinces and international sales focusing on Europe, America, and Asia[8] - The company's B-vitamin products are water-soluble and mainly participate in enzyme system activities as coenzymes or cofactors[8] - The company's business is divided into three major segments: B-vitamins, other vitamins, and fine chemical products[8] - The company's global competitiveness is strong, with a diverse product portfolio including Vitamin B6, B1, biotin, folic acid, and other fine chemical products like ABL[21] - The company holds a leading global market share in Vitamin B6 and Vitamin B1, and is in the top tier for biotin and folic acid products[62] - The company has a well-established sales and service network, with products sold in Asia, Europe, North America, South America, Oceania, and Africa[68] Research and Development - The company's R&D efforts are supported by its subsidiary Shanghai Bonasain and its technology center, focusing on product optimization and new product development[66] - R&D expenses increased by 3.58% to 38,417,883.89 RMB[80] - Internal R&D expenditures are classified into research and development phases, with research phase expenses expensed as incurred and development phase expenses capitalized if specific criteria are met[127] Environmental and Social Responsibility - The company has a robust environmental protection system, including wastewater treatment, waste gas management, and hazardous waste treatment facilities[67] - The company has established a comprehensive management system, including quality, environmental, and occupational health and safety management systems, with certifications such as FDA, CEP, and ISO standards[65] - The company's emissions of particulate matter, SO2, and NOX are within the permissible limits, with no instances of exceeding the standards[132] - The company has invested 250,000 yuan in poverty alleviation and rural revitalization projects, benefiting approximately 1,000 people through educational support[137] - The company operates 5 wastewater pretreatment workshops, 3 sewage treatment stations, 2 sets of waste gas treatment systems, and 1 hazardous waste treatment center, all of which are functioning stably[133] - The company has not received any environmental penalties during the reporting period due to non-compliance or inadequate monitoring[133] - The company's VOCs emissions are 12.05mg/m³, which is significantly below the standard limit of 100mg/m³, with an annual emission of 87.36t[152] - CODcr emissions are 39.2mg/m³, below the final direct discharge standard of 60mg/L, with an annual emission of 119.8t[152] - Ammonia nitrogen emissions are 0.84mg/m³, well below the final direct discharge standard of 8mg/L, with an annual emission of 16.17t[152] - Particulate matter emissions from the thermal power plant are 1.97mg/m³, below the standard limit of 10mg/m³, with an annual emission of 10.18t[152] - SO₂ emissions from the thermal power plant are 11.82mg/m³, below the standard limit of 35mg/m³, with an annual emission of 10.72t[152] - NOX emissions from the thermal power plant are 23.73mg/m³, below the standard limit of 50mg/m³, with an annual emission of 50.89t[152] - The company has implemented energy-saving measures, including new equipment and technologies, resulting in a reduction in energy consumption per unit of main products[158] - The company has established a comprehensive environmental management system and passed environmental management system certification[157] - The company conducts regular environmental monitoring using both manual and online methods, with data uploaded in real-time to environmental authorities[155] - The company has developed an emergency response plan for environmental incidents, which was filed with the local environmental bureau in April 2021[154] Shareholder and Equity Information - The company distributed RMB -310,823,800.00 to shareholders during the period[19] - Total owner's equity increased by RMB 405,522,820.10, with retained earnings growing by RMB 400,554,808.56[19] - Owner's equity at the end of the period was RMB 4,082,082,011.58, with a capital reserve of RMB 1,981,933,320.43[25] - Comprehensive income for the period was RMB 401,248,794.80, contributing to the increase in owner's equity[25] - The company's total registered capital is RMB 437.78 million, with a total share capital of 437.78 million shares, each with a par value of RMB 1[34] - The company has seven subsidiaries included in its consolidated financial statements, such as Lepingshi Tianxin Thermal Power Co., Ltd. and Shanghai Bonasain Pharmaceutical R&D Co., Ltd[35] - The company recorded a total of 4,968,011.54 in equity-based compensation for the period[43] - The total equity balance at the end of the period was 2,314,914,198.45[45] - Comprehensive income for the period totaled 400,554,808.56 RMB[46] - Owner's capital contributions and reductions amounted to 4,968,011.54 RMB, primarily from share-based payments[46] - The ending balance for the period was 2,304,976,059.61 RMB[46] - The beginning balance of owner's equity was 4,063,022,747.23 RMB[48] - Total comprehensive income for the period was 344,607,638.98 RMB[48] - Owner's capital contributions and reductions were 4,968,011.54 RMB, mainly from share-based payments[48] - Profit distribution included a reduction of 310,823,800.00 RMB[48] - The beginning balance of consolidated owner's equity was 4,057,981,639.72 RMB[56] - Total comprehensive income for the period was 329,956,160.32 RMB[56] - Owner's capital contributions and reductions were 4,968,011.54 RMB[56] - The largest shareholder, Xu Jiangnan, holds 203,603,970 restricted shares with a lock-up period until January 11, 2026[195] - The second-largest shareholder, Xu Jing, holds 59,110,830 restricted shares with the same lock-up period[195] - The company's largest shareholder, Xu Jiangnan, holds 203,603,970 shares, representing 46.51% of the total shares, all of which are restricted shares[150] - Xu Jing, the second-largest shareholder, holds 59,110,830 shares, accounting for 13.50% of the total shares, all of which are restricted shares[150] - Wang Guangtian, the third-largest shareholder, holds 56,803,200 shares, representing 12.98% of the total shares, all of which are restricted shares[150] - Qiu Qinyong, the fourth-largest shareholder, holds 35,502,000 shares, accounting for 8.11% of the total shares, all of which are restricted shares[150] - The company has committed to stabilizing its stock price within three years of listing by implementing a stock repurchase plan if the stock price falls below the net asset value per share for 20 consecutive trading days[145] - The controlling shareholder and actual controller have pledged to support the stock price stabilization plan by voting in favor of stock repurchase proposals and increasing their shareholdings if necessary[145] - The company has established a lock-up period of 36 months for shares held by certain entities, during which they cannot transfer or entrust others to manage the shares[142] - After the lock-up period, shareholders are allowed to reduce their holdings, but they must announce the reduction three trading days in advance and comply with relevant laws and regulations[142] - If the stock price falls below the issue price for 20 consecutive trading days within six months of listing, the lock-up period for certain shares will be automatically extended by at least six months[142] - The company has committed to avoiding competition with its subsidiaries and will transfer any competing business opportunities to the subsidiaries or third parties to eliminate potential conflicts[145] - The company has committed to not transferring or entrusting others to manage its directly or indirectly held shares before the IPO for 36 months from the listing date[164] - The company will strictly regulate related-party transactions with its wholly-owned, controlled subsidiaries, and other entities under actual control[164] - The company will follow fair, just, and open principles for unavoidable related-party transactions, signing relevant agreements and fulfilling decision-making and disclosure obligations[164] - The company ensures that all transactions with its subsidiaries and controlled entities will strictly follow market rules and commercial principles[164] - The company will avoid using its controlling shareholder status to harm the interests of the company and other shareholders through related-party transactions[164] - The company will not directly or indirectly borrow, occupy, or otherwise misappropriate the company's funds or assets[164] - The company has disclosed all equity or interests held directly or indirectly in other enterprises or economic organizations[165] - The company and its controlled entities will not engage in any business activities that compete directly or indirectly with the company's main business[165] - The company will ensure that its controlled entities do not seek commercial opportunities belonging to the company or its subsidiaries[165] - The company will take necessary measures to correct and remedy any violations of the above commitments and bear compensation for any losses caused[165] - The company has committed to avoiding any business activities that directly or indirectly compete with Tianxin Pharmaceutical, including ceasing sales of similar products and not engaging in any competitive business opportunities[167] - The company will not provide business qualifications, operating licenses, proprietary technologies, sales channels, or customer information to any entities that compete with Tianxin Pharmaceutical[167] - The company will reduce and regulate related-party transactions with Tianxin Pharmaceutical, ensuring they are conducted at fair market prices and in compliance with legal and regulatory requirements[168] Legal and Compliance - The company has no significant litigation or arbitration matters during the reporting period[170] - The company and its controlling shareholders are not involved in any illegal activities or subject to penalties, and there are no significant debts overdue[170] Investments and Capital Expenditures - Investment in the first half of 2023 was RMB 104.5 million, a 1507.69% increase compared to the same period last year[96] - The company's subsidiary, Ningxia Tianxin Pharmaceutical Co., Ltd., is investing RMB 890 million in a fine chemical products and supporting thermal power project[99] - The company's trading financial assets decreased by 100% due to the redemption of financial products[93] - Other current assets decreased by 67.40% due to a reduction in VAT credits[93] - Construction in progress increased by 55.53% due to increased engineering investments[93] - Intangible assets grew by 77.43% due to the acquisition of new land use rights[93] - Other non-current assets increased by 180.98% due to prepayments for long-term

证券代码：603235 证券简称：天新药业 公告编号：2023-015 江西天新药业股份有限公司 关于参加江西辖区上市公司 2023 年投资者 网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为进一步加强与投资者的互动交流，江西天新药业股份有限公司（以下简 称"公司"）将参加由江西证监局、江西省上市公司协会与深圳市全景网络有 限公司联合举办的"2023 年江西辖区上市公司投资者集体接待日活动"，现将 相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 (https://rs.p5w.net)，或关注微信公众号：全景财经，或下载全景路演 APP，参 与本次互动交流，活动时间为 2023 年 5 月 19 日（周五）14:30-17:00。届时公 司高管将在线就公司 2022 年度业绩、公司治理、发展战略、经营状况、融资计 划、股权激励和可持续发展等投资者关心的问题，与投资者进行沟通与交流， 欢迎广大投资者踊跃参与。 特此公告。 江西天新药业股份有限公司 2023 年 5 ...